We are here for you

In the face of COVID-19 challenges and the burden on the healthcare system during this time, Pacira remains committed to supporting our healthcare partners.

Pacira is available if you have questions—click here to be connected with a representative. Pacira has also put together this page to answer some of your current relevant questions.

Is EXPAREL currently available?

Yes, EXPAREL is available. Both EXPAREL 266 mg/20 mL and 133 mg/10 mL are available in cartons of 4 or 10 vials and may be ordered directly from Pacira.

While the COVID-19 virus has created restrictions on global supply chains and limitations on the availability of some medications,1 this has not affected EXPAREL supply. EXPAREL is manufactured in the United States and the United Kingdom, and is fully stocked to meet surgical demand. Learn more about ordering EXPAREL.

With restrictions on in-person engagements in hospital/surgical facilities, where can I find EXPAREL resources and support?

Even with social distancing and the current healthcare constraints on visitors and deliveries, Pacira is here to help. Pacira provides extensive resources on to ensure healthcare providers have easy access to the information they need. You can find all of the available resources here.

For additional support, click here to be contacted by a Pacira representative.

Is someone available to answer reimbursement questions?

Yes, the EXPAREL reimbursement helpline at 855-793-9727 is available to answer your questions about billing and reimbursement for EXPAREL. You may also click here to learn more about reimbursement.

How is postsurgical pain management creating additional challenges for surgical facilities?

The increasing stress and limitations on hospital resources, beds, and personnel—plus, the substantial risk of exposure to COVID-19—have heightened the urgency to minimize the postsurgical recovery period in surgical facilities.2,3

Optimized postsurgical pain control with fewer opioids can help achieve this goal.

  • Postsurgical pain control is essential for improving recovery and achieving recovery milestones faster4-7
  • Minimizing opioids reduces the risk of ORAEs and the associated risk of delayed recovery goals5,8-10
  • Optimize resource utilization with faster ambulation and hospital discharge4-7
  • Reduce readmissions, which often occur due to postsurgical pain11,12
How can effective postsurgical pain management help expedite patient recovery and discharge?

Appropriate multimodal protocols with EXPAREL are key to providing optimal pain control and improving patient recovery.

EXPAREL provides long-lasting, non-opioid pain control, from surgery to discharge to home, which may help relieve the pressure on hospital staff.4-7,9

  • Enables faster achievement of recovery milestones for earlier ambulation, less time to discharge, and shorter LOS4-7
  • Minimizes opioid use and risk of ORAEs5,9,10*
  • Eliminates the need for resource-intensive catheters and pumps13

Learn about long-lasting, non-opioid postsurgical pain control with EXPAREL.

See how EXPAREL improves recovery and shortens LOS.

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

To limit risk of COVID-19 transmission during anesthesia, what are the current recommendations for providing effective postsurgical pain control with regional approaches?

In response to the current crisis, new recommendations suggest using regional anesthesia over general anesthesia to reduce the need for aerosol-generating medical procedures.14

This may be especially important for COVID-19–positive patients or those at risk for having the virus but who are not yet showing symptoms.14

Regional analgesia is also beneficial for patients because it lowers the risk of postoperative complications.14

There are several techniques for using EXPAREL as part of a regional analgesia plan to provide long-lasting pain control. Learn about the versatility of EXPAREL in abdominal or PEC field blocks here and in interscalene brachial plexus nerve blocks here.

As hospitals and ASCs follow recommendations to postpone nonessential surgeries, what considerations should be taken into account for those procedures that must be performed?

During this crisis, the goal will be to reduce COVID-19 exposure risks and resource utilization by limiting procedures and enabling rapid hospital discharge.2,3

Maximizing postsurgical pain control while minimizing opioid use can help

  • Improve recovery and achieve recovery milestones faster4-7
  • Reduce the risk of ORAEs and the associated risk of delayed recovery goals5,8-10
  • Optimize resource utilization with faster ambulation and hospital discharge4-7
  • Reduce PACU delays and hospital readmissions11,12

Learn more about faster achievement of recovery goals with long-lasting, non-opioid EXPAREL.


For more information, click here to contact a Pacira representative.